GlassScriptPhysician profile
Dominic Mirarchi
NPI 1790776078
$1,738.57
in general payments reported to CMS, 2019-2025
28 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $118 · 2021: $11.56 · 2023: $433 · 2024: $568 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331.43 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $321.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $226.38 | 2023-2025 | |
| Shield Therapeutics INC | $110.23 | 2024-2025 | |
| Lilly USA, LLC | $84.56 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $65.54 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $56.07 | 2019-2025 | Camzyos, Eliquis |
| Dexcom, INC. | $52.04 | 2023-2025 | Dexcom G6 Transmitter |
| Biofire Diagnostics, LLC | $48.41 | 2019 | |
| Astellas Pharma US INC | $42.68 | 2020-2023 | Myrbetriq |
| Amgen INC. | $41.31 | 2019-2020 | |
| Pfizer INC. | $40.08 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $39.81 | 2024 | Austedo Xr, Ajovy |
| Amarin Pharma, INC. | $27.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.27 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.26 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $23.04 | 2019-2020 | |
| Strongbridge US INC. | $19.50 | 2019 | |
| Ibsa Pharma INC. | $18.52 | 2025 | Licart, Flector, Tirosint |
| Nestle Healthcare Nutrition INC. | $18.10 | 2023 | |
| Sanofi Pasteur INC. | $18.04 | 2019 | |
| Sumitomo Pharma America, INC. | $17.55 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $17.38 | 2023 | Inspire |
| Tactile Systems Technology INC | $16.04 | 2023 | Entre Plus, Flexitouch Plus |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2019 | |
| Cequr Corporation | $12.89 | 2024 | Cequr Simplicity |
| Ironshore Pharmaceuticals INC. | $12.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominic Mirarchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.